Opendata, web and dolomites

METAdiag

METAdiag: Diagnose to Cure

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 METAdiag project word cloud

Explore the words cloud of the METAdiag project. It provides you a very rough idea of what is the project "METAdiag" about.

damages    status    proprietary    overlooked    appear    consumption    balanced    initially    generate    million    abnormal    expecting    earlier    people    life    errors    debilitating    as    stay    feasibility    hire    tests    impairments    levels    hallmark    serious    accuracy    cancer    diet    boost    platform    energetics    milestones    monitor    reliability    organisms    symptoms    patients    mechanism    influencing    metabolic    commercial    economic    cell    reverted    impaired    detect    22    despite    lifelong    quantifying    proving    healthy    diabetes    uniquely    metafora    clinical    nutrient    living    conduct    impacts    small    diagnosis    invasive    detection    surface    transporters    first    diseases    correctly    fact    receive    prognosis    therapies    perspectives    company    42    clinicians    subjects    burden    energetic    metabolism    cells    adapt    damage    inborn    feed    overfeeding    starting    metadiag    revenues    onset    time    quality    longer    conversely    starving    financial    function    prevent    turn    market    progress    incur    poorer    diagnostic    positioned    network    treatments    entail   

Project "METAdiag" data sheet

The following table provides information about the project.

Coordinator
METAFORA BIOSYSTEMS 

Organization address
address: 29 RUE DU FAUBOURG SAINT JACQUES
city: PARIS
postcode: 75014
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.metafora-biosystems.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    METAFORA BIOSYSTEMS FR (PARIS) coordinator 50˙000.00

Map

 Project objective

As all living organisms, our cells need to feed on a balanced diet to stay healthy and correctly function. To do that, cells adapt their nutrient consumption according to their energetic needs. If the uptake mechanism is impaired, it impacts cell metabolism. Both starving cells & overfeeding cells are a hallmark for the onset and progress of serious diseases like diabetes, cancer or inborn errors of metabolism, which can all be seen as metabolic diseases. These are debilitating conditions that need lifelong treatments, entail poorer life quality and incur a major economic burden. Subjects appear initially healthy and symptoms are often overlooked, but by the time of diagnosis, damage can no longer be reverted. Conversely, early detection could prevent most of the damages by starting specific therapies. However, despite the fact that all metabolic diseases have abnormal cell energetics, there are no tests for cell metabolism in clinical practice. In response, we at METAFORA aim to bring to market METAdiag, the first diagnostic platform able to assess and monitor the metabolic status of our cells. This unique and non-invasive diagnostic system is able to detect abnormal cell energetics by quantifying the levels of nutrient transporters at the cell surface. After proving the reliability and accuracy of our platform at a small scale, we now aim to take a step further towards the market. Thus, in Phase 1 we aim to conduct a Feasibility Study that will help us to assess and achieve the significant milestones influencing the project from the technical, commercial and financial perspectives. Based on proprietary technology and on a strong collaboration network, METAdiag will be uniquely positioned to detect metabolic impairments, allowing clinicians to achieve an earlier diagnosis and patients to receive better management and prognosis. In turn, METAdiag will boost the growth of our company, expecting to generate €42 million in revenues and to hire 22 new people in 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "METADIAG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "METADIAG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More